George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
|Articles|September 16, 2008
- May 15 2003
- Volume 10
- Issue 9
AFFORDABLE HOUSING
Author(s)Michael Sheehan
Advertisement
Financial experts who have forecastedan end to the rise in real estateprices have yet to see their predictionscome true. Despite higherprices, however, a new home is stillan affordable option for mostAmericans, according to a recent statisticalsurvey. The survey shows thatthe average home costs 3.6 timesmore than the average household income,up from 3.2 times the averagehousehold income 3 years ago, butstill well within the range of pricesover the past 2 decades. Because ofplunging interest rates, the medianpercentage of household income devotedto mortgage payments is 22%,the same level it was at in 1999.
Articles in this issue
about 18 years ago
Postwar Economy Refocuses Attentionabout 18 years ago
Model Portfolio Series: Conservative Growthabout 18 years ago
How Does Your Financial IQ Measure Up?about 18 years ago
History Provides Lessons in Investingabout 18 years ago
Read the Market's Long-Term Performanceabout 18 years ago
Less Is More When Buying Stock Spinoffsabout 18 years ago
Weigh the Aspects of Variable Annuitiesabout 18 years ago
Maximize Your Sale of Stocks at a Lossabout 18 years ago
Realize the Importance of Market Timingabout 18 years ago
Speed Through Annual Reports Like a ProAdvertisement
Related to this article
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.
Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.
Advertisement
Advertisement
Trending on HCPLive
1
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
2
FAQ: What the Expanded Marstacimab Approval Means for Hemophilia A, B
3
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5